ES2073398T3 - Nuevos derivados substituidos del acido bencilideno- y cinamilideno-malonico con actividad como inhibidores de la proliferacion celular. - Google Patents

Nuevos derivados substituidos del acido bencilideno- y cinamilideno-malonico con actividad como inhibidores de la proliferacion celular.

Info

Publication number
ES2073398T3
ES2073398T3 ES88121405T ES88121405T ES2073398T3 ES 2073398 T3 ES2073398 T3 ES 2073398T3 ES 88121405 T ES88121405 T ES 88121405T ES 88121405 T ES88121405 T ES 88121405T ES 2073398 T3 ES2073398 T3 ES 2073398T3
Authority
ES
Spain
Prior art keywords
inhibitors
malonico
cinamilideno
bencilideno
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88121405T
Other languages
English (en)
Inventor
Alexander Levitzki
Chaim Gilon
Michael Chorev
Aviv Gazit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL84937A external-priority patent/IL84937A/xx
Priority claimed from IL88354A external-priority patent/IL88354A0/xx
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of ES2073398T3 publication Critical patent/ES2073398T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Steroid Compounds (AREA)

Abstract

SE PROVEEN COMPOSICIONES FARMACEUTICAS CONTENIENDO SEGUN UN INGREDIENTE ACTIVO UN COMPUESTO DE FORMULA GENERAL (I) DESCRITA EN MEMORIA,DONDE R1 Y R2 SON CADA UNO E INDEPENDIENTEMENTE CN, CONH2 O COOH O SOLO UNO DE R1 Y R2 PUEDE SER - CSNH2 O, CUANDO R1 ES CN R2 PUEDE TAMBIEN SER EL GRUPO (I): SIENDO R3 HIDROGENO, CH3 U OH, R4, R5, R6, R7 SON CADA UNO INDEPENDIENTEMENTE H, OH, C1 -5 ALQUIL, C1 - 5 ALCOXI, NH2, CHO, HALOGENO, NO2 O COOH, O R4 Y R5 PUEDEN REPRESENTAR A LA VEZ UN GRUPO - O - CH2 - O -; ENTENDIENDO QUE: (A) CUANDO R4 Y R7 SON CADA UNO OH, R3, R5 Y R6 SON CADA UNO H Y UNO DE ENTRE R1 Y R2 ES CN, ENTONCES EL OTRO DE ENTRE R1 Y R2 NO PUEDE SER CONH2; Y (B) CUANDO R3 Y R7 SON CADA UNO H, R5 ES OH Y R4 Y R6 SON AMBOS H O AMBOS C1 - 5 ALQUIL, ENTONCES R1 ES CN Y R2 ES CN O EL GRUPO (II), O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ELLOS. TAMBIEN SE PROVEEN ALGUNOS NUEVOS COMPUESTOS DE LA FORMULA (I) CITADA. LAS COMPOSICIONES Y COMPUESTOS DE ACUERDO AL INVENTO SON EFICIENTES INHIBIDORESDE ENCIMAS DE TIROSINA PROTEICA Y SON UTILES PARA LA INHIBICION DE PROCESOS PROLIFERATIVOS EN CELULAS DE MAMIFEROS.FIG 1.
ES88121405T 1987-12-24 1988-12-21 Nuevos derivados substituidos del acido bencilideno- y cinamilideno-malonico con actividad como inhibidores de la proliferacion celular. Expired - Lifetime ES2073398T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL84937A IL84937A (en) 1987-12-24 1987-12-24 Pharmaceutical compositions comprising benzylidene- malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
IL88354A IL88354A0 (en) 1988-11-10 1988-11-10 Pharmaceutical compositions comprising benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells,certain such novel compounds and their preparation

Publications (1)

Publication Number Publication Date
ES2073398T3 true ES2073398T3 (es) 1995-08-16

Family

ID=26321754

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88121405T Expired - Lifetime ES2073398T3 (es) 1987-12-24 1988-12-21 Nuevos derivados substituidos del acido bencilideno- y cinamilideno-malonico con actividad como inhibidores de la proliferacion celular.

Country Status (8)

Country Link
EP (2) EP0614661A3 (es)
JP (2) JP2806954B2 (es)
AT (1) ATE120955T1 (es)
AU (1) AU632992B2 (es)
CA (1) CA1334826C (es)
DE (1) DE3853577T2 (es)
ES (1) ES2073398T3 (es)
NZ (1) NZ227436A (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68917357T2 (de) * 1988-04-28 1995-01-26 Suntory Ltd Derivate der Coffeinsäure und pharmazeutische Zusammensetzungen, die sie enthalten.
EP0527181A4 (en) * 1990-04-16 1993-04-07 Rorer International (Holdings) Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
DE4230262A1 (de) * 1992-09-10 1994-03-17 Behringwerke Ag Substituierte Phenole, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von zellproliferationsbedingten Erkrankungen
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
GB9802522D0 (en) 1998-02-06 1998-04-01 Montford University De Hydroxylation activated prodrugs
DE69918950T2 (de) * 1998-02-06 2005-07-28 De Montfort University Durch hydroxylierung aktivierte medikamentvorstufen
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
RU2277531C9 (ru) * 2000-04-13 2006-11-20 Эйч Эс Си Рисерч Энд Дивелопмент Лимитед Партнершип Новые соединения для модулирования клеточной пролиферации
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
MXPA04000695A (es) * 2001-07-23 2005-08-26 Galileo Pharmaceuticals Inc Compuestos citoprotectores, formulaciones farmaceuticas y cosmeticas y metodos.
EP1453500A1 (en) * 2001-10-11 2004-09-08 The Hospital For Sick Children Styryl acrylonitrile compounds and their use to promote myelopoiesis
US7598419B2 (en) 2004-03-26 2009-10-06 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
NZ585357A (en) 2007-10-29 2012-02-24 Natco Pharma Ltd Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
SMT202300445T1 (it) 2014-07-03 2024-03-13 Silti Ag Metodi e composizioni per trattare l’obesità, prevenire l’aumento di peso, promuovere la perdita di peso, promuovere il dimagrimento, o trattare o prevenire lo sviluppo del diabete
CA3226009A1 (en) * 2018-10-04 2020-04-09 Murata Manufacturing Co., Ltd. Additives for electrolytes in li-ion batteries
AU2022332335A1 (en) 2021-08-25 2024-04-11 García Sada, Fernando Compositions and methods for preventing or reducing the risk of metabolic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3522188A (en) * 1962-06-27 1970-07-28 Gaf Corp Use of alpha-alkyl (or alkenyl) benzylidene malononitriles as u.v. absorbers,and stabilized compositions and light filters containing same
AU500541B2 (en) * 1975-09-29 1979-05-24 Ici Australia Limited Substituted benzylidene malonitriles
US4064266A (en) * 1975-09-29 1977-12-20 Ici Australia Limited Compositions for killing internal parasites containing 3-tert-alkyl-4-hydroxy-5-halo-benzylidene-malonitriles
JPS6239523A (ja) * 1985-08-14 1987-02-20 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
US4781750A (en) * 1985-08-27 1988-11-01 Rohm And Haas Company Herbicidally active enols
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
DE68917357T2 (de) * 1988-04-28 1995-01-26 Suntory Ltd Derivate der Coffeinsäure und pharmazeutische Zusammensetzungen, die sie enthalten.

Also Published As

Publication number Publication date
DE3853577T2 (de) 1995-08-31
EP0614661A3 (en) 1994-11-02
EP0322738A2 (en) 1989-07-05
EP0322738A3 (en) 1991-05-08
ATE120955T1 (de) 1995-04-15
DE3853577D1 (de) 1995-05-18
AU2736088A (en) 1989-06-29
JP2806954B2 (ja) 1998-09-30
AU632992B2 (en) 1993-01-21
EP0614661A2 (en) 1994-09-14
EP0322738B1 (en) 1995-04-12
JPH10279477A (ja) 1998-10-20
JPH02138238A (ja) 1990-05-28
CA1334826C (en) 1995-03-21
NZ227436A (en) 1992-10-28

Similar Documents

Publication Publication Date Title
EP0614661A3 (en) Benzylidene and cinnamylidene malononitrile derivatives to inhibit proliferative processes in mammalian cells.
ZA857523B (en) Pharmaceutical compositions containing diazepines and having a paf-antagonistic activity
FI810250L (fi) Foerfarande foer framstaellning av nya terapeutiskt aktiva heterocykliska foereningar
ATE163412T1 (de) Pyridazine als interleukin-1-beta verwandlungsenzym inhibitoren
DE68925223D1 (de) 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-en-2-carbonsäure-Verbindungen
NO824062L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.
ATE51618T1 (de) Imidazolderivate, verfahren zu deren herstellung, deren anwendung und pharmazeutische zusammenstellungen.
CA2010639A1 (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2-thiones
ATE18196T1 (de) 1,4-acyloxynaphthalenderivate, diese enthaltende kompositionen, verfahren fuer ihre herstellung und zwischenprodukte dafuer.
ES2000456A6 (es) Procedimiento para preparar deirvados de acido eicosatriinoico-5,8,11 y utilizacion de estos en composiciones farmaceuticas y cosmeticas.
DK663588D0 (da) Hidtil ukendte forbindelser
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
DE3668888D1 (de) Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.
ATE62663T1 (de) Indan-derivate, verfahren zu ihrer herstellung und die erhaltenen zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen.
MA19434A1 (fr) Procede de preparation de nouvelles imidazo/i, 2-a/quinoleines et de leurs sels
ES8607235A1 (es) "4-(nitrofenil)-tetrahidropiridinas,procedimiento para su obtencion y su empleo como medicamento"
ES552486A0 (es) Un procedimiento para la obtencion de compuestos de 1-oxa-1-dertia cefalosporina.
GB1203430A (en) Heterocyclic spiro compounds
GB1135947A (en) Novel biologically active derivatives of phenanthridone
GB1327042A (en) Oxazole derivatives their preparation and pharmaceutical compositions containing the same
ES8502426A1 (es) Procedimiento para preparar nuevas semicarbazidas
GB1175169A (en) Tryptamine Compounds
ATE73801T1 (de) Heterocyclische oxophthalazinylessigsaeure.
YU106191A (sh) Aminobenzodiazepini

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 322738

Country of ref document: ES